PRQR logo

ProQR Therapeutics NV (PRQR) Cash From Investing

Annual CFI

$4.63 M
+$5.37 M+725.61%

31 December 2023

1-Year Change

+725.61%
PRQR annual cash flow from investing activities is up +725.61% year-on-year

3-Year Change

+538.91%
PRQR annual cash flow from investing activities is up +538.91% over the past 3 years

All-time High

$4.63 M
PRQR annual cash flow from investing activities is currently at an all-time high

Sector Rank

73.79%
PRQR annual cash flow from investing activities is higher than 73.79% of companies in Healthcare sector
Annual CFF-$2.46 M
PRQR annual cash flow from financing activities is -$2.46 million
Annual CFO$23.33 M
PRQR annual cash flow from operations is $23.33 million
Annual FCF$21.84 M
PRQR annual free cash flow is $21.84 million
Annual CAPEX$1.48 M
PRQR annual capital expenditures is $1.48 million

PRQR Cash From Investing Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly CFI

$17.97 M
+$18.09 M+15072.67%

01 September 2024

1-Year Change

+4975.77%
PRQR quarterly cash flow from investing activities is up +4975.77% year-on-year

3-Year Change

+8903.14%
PRQR quarterly cash flow from investing activities is up +8903.14% over the past 3 years

All-time High

$17.97 M
PRQR quarterly cash flow from investing activities is currently at an all-time high

Sector Rank

87.74%
PRQR quarterly cash flow from investing activities is higher than 87.74% of companies in Healthcare sector
Quarterly CFF-$514.40 K
PRQR quarterly cash flow from financing activities is -$514.40 thousand
Quarterly CFO-$6.71 M
PRQR quarterly cash flow from operations is -$6.71 million
Quarterly FCF-$7.05 M
PRQR quarterly free cash flow is -$7.05 million
Quarterly CAPEX$337.60 K
PRQR quarterly capital expenditures is $337.60 thousand

PRQR Quarterly CFI Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM CFI

$4.00 M
+$18.34 M+127.94%

01 September 2024

1-Year Change

+600.47%
PRQR TTM cash flow from investing activities is up +600.47% year-on-year

3-Year Change

+1057.74%
PRQR TTM cash flow from investing activities is up +1057.74% over the past 3 years

All-time High

$4.63 M
PRQR TTM cash flow from investing activities is currently -13.54% below its historical high of $4.63 million

Sector Rank

75.39%
PRQR TTM cash flow from investing activities is higher than 75.39% of companies in Healthcare sector
TTM CFF-$2.44 M
PRQR TTM cash flow from financing activities is -$2.44 million
TTM CFO-$35.67 M
PRQR TTM cash flow from operations is -$35.67 million
TTM FCF-$37.73 M
PRQR TTM free cash flow is -$37.73 million
TTM CAPEX$2.06 M
PRQR TTM capital expenditures is $2.06 million

PRQR TTM CFI Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PRQR Cash From Investing Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+725.6%+4975.8%+600.5%
3 y3 years+538.9%+8903.1%+1057.7%
5 y5 years+1357.2%+10000.0%+1062.3%

PRQR Cash From Investing High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 yearsat high+538.9%at high+193.3%-13.5%+127.5%
5 y5 yearsat high+538.9%at high+193.3%-13.5%+127.5%
alltimeall timeat high+264.8%at high+193.3%-13.5%+127.5%

ProQR Therapeutics NV Cash From Investing History

DateAnnualQuarterlyTTM
Sept 2024
-
$17.97 M(<-9900.0%)
$4.00 M(-127.9%)
June 2024
-
-$120.00 K(-99.4%)
-$14.33 M(-1.4%)
Mar 2024
-
-$19.26 M(-455.5%)
-$14.53 M(-413.8%)
Dec 2023
$4.63 M(-725.6%)
$5.42 M(-1570.1%)
$4.63 M(-678.9%)
Sept 2023
-
-$368.50 K(+14.4%)
-$800.10 K(+22.7%)
June 2023
-
-$322.00 K(+236.8%)
-$652.00 K(+16.0%)
Mar 2023
-
-$95.60 K(+582.9%)
-$562.20 K(-24.1%)
Dec 2022
-$740.30 K(+47.2%)
-$14.00 K(-93.6%)
-$740.40 K(-19.9%)
Sept 2022
-
-$220.40 K(-5.1%)
-$923.90 K(+1.8%)
June 2022
-
-$232.20 K(-15.2%)
-$907.60 K(+23.0%)
Mar 2022
-
-$273.80 K(+38.6%)
-$738.10 K(+46.8%)
Dec 2021
-$502.90 K(-52.3%)
-$197.50 K(-3.2%)
-$502.90 K(+20.3%)
Sept 2021
-
-$204.10 K(+225.5%)
-$418.10 K(-25.3%)
June 2021
-
-$62.70 K(+62.4%)
-$559.60 K(-36.1%)
Mar 2021
-
-$38.60 K(-65.7%)
-$875.30 K(-17.0%)
Dec 2020
-$1.06 M(+62.5%)
-$112.70 K(-67.4%)
-$1.06 M(-13.0%)
Sept 2020
-
-$345.60 K(-8.7%)
-$1.21 M(+34.9%)
June 2020
-
-$378.40 K(+73.2%)
-$899.00 K(+46.3%)
Mar 2020
-
-$218.50 K(-19.1%)
-$614.40 K(-5.4%)
Dec 2019
-$649.30 K
-$270.10 K(+744.1%)
-$649.20 K(+56.0%)
Sept 2019
-
-$32.00 K(-65.9%)
-$416.10 K(-15.7%)
June 2019
-
-$93.80 K(-63.0%)
-$493.40 K(-20.0%)
DateAnnualQuarterlyTTM
Mar 2019
-
-$253.30 K(+584.6%)
-$616.80 K(+67.4%)
Dec 2018
-$368.40 K(+168.9%)
-$37.00 K(-66.1%)
-$368.40 K(+9.0%)
Sept 2018
-
-$109.30 K(-49.7%)
-$337.90 K(+31.6%)
June 2018
-
-$217.20 K(+4332.7%)
-$256.80 K(+173.2%)
Mar 2018
-
-$4900.00(-24.6%)
-$94.00 K(-31.4%)
Dec 2017
-$137.00 K(-95.1%)
-$6500.00(-77.0%)
-$137.00 K(-12.1%)
Sept 2017
-
-$28.20 K(-48.2%)
-$155.80 K(-72.7%)
June 2017
-
-$54.40 K(+13.6%)
-$570.30 K(-75.2%)
Mar 2017
-
-$47.90 K(+89.3%)
-$2.30 M(-18.0%)
Dec 2016
-$2.81 M(+91.3%)
-$25.30 K(-94.3%)
-$2.81 M(-6.6%)
Sept 2016
-
-$442.70 K(-75.2%)
-$3.01 M(+14.2%)
June 2016
-
-$1.79 M(+222.9%)
-$2.63 M(+78.9%)
Mar 2016
-
-$553.80 K(+147.9%)
-$1.47 M(+0.2%)
Dec 2015
-$1.47 M(-10.4%)
-$223.40 K(+224.2%)
-$1.47 M(-30.0%)
Sept 2015
-
-$68.90 K(-89.0%)
-$2.10 M(-15.2%)
June 2015
-
-$626.30 K(+13.7%)
-$2.47 M(+25.1%)
Mar 2015
-
-$550.60 K(-35.4%)
-$1.98 M(+20.5%)
Dec 2014
-$1.64 M(+801.4%)
-$852.50 K(+91.9%)
-$1.64 M(+108.3%)
Sept 2014
-
-$444.30 K(+243.9%)
-$787.20 K(+129.6%)
June 2014
-
-$129.20 K(-39.5%)
-$342.90 K(+60.5%)
Mar 2014
-
-$213.70 K
-$213.70 K
Dec 2013
-$181.90 K
-
-

FAQ

  • What is ProQR Therapeutics NV annual cash flow from investing activities?
  • What is the all time high annual CFI for ProQR Therapeutics NV?
  • What is ProQR Therapeutics NV annual CFI year-on-year change?
  • What is ProQR Therapeutics NV quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for ProQR Therapeutics NV?
  • What is ProQR Therapeutics NV quarterly CFI year-on-year change?
  • What is ProQR Therapeutics NV TTM cash flow from investing activities?
  • What is the all time high TTM CFI for ProQR Therapeutics NV?
  • What is ProQR Therapeutics NV TTM CFI year-on-year change?

What is ProQR Therapeutics NV annual cash flow from investing activities?

The current annual CFI of PRQR is $4.63 M

What is the all time high annual CFI for ProQR Therapeutics NV?

ProQR Therapeutics NV all-time high annual cash flow from investing activities is $4.63 M

What is ProQR Therapeutics NV annual CFI year-on-year change?

Over the past year, PRQR annual cash flow from investing activities has changed by +$5.37 M (+725.61%)

What is ProQR Therapeutics NV quarterly cash flow from investing activities?

The current quarterly CFI of PRQR is $17.97 M

What is the all time high quarterly CFI for ProQR Therapeutics NV?

ProQR Therapeutics NV all-time high quarterly cash flow from investing activities is $17.97 M

What is ProQR Therapeutics NV quarterly CFI year-on-year change?

Over the past year, PRQR quarterly cash flow from investing activities has changed by +$18.34 M (+4975.77%)

What is ProQR Therapeutics NV TTM cash flow from investing activities?

The current TTM CFI of PRQR is $4.00 M

What is the all time high TTM CFI for ProQR Therapeutics NV?

ProQR Therapeutics NV all-time high TTM cash flow from investing activities is $4.63 M

What is ProQR Therapeutics NV TTM CFI year-on-year change?

Over the past year, PRQR TTM cash flow from investing activities has changed by +$4.80 M (+600.47%)